Preparation method of PARP7 inhibitor Atamparib (RBN-2397)
Through a series of compound reaction steps, the efficient and highly selective PARP7 inhibitor RBN-2397 was successfully prepared, which solved the problem of the development of PARP7 inhibitors in the prior art, achieved effective inhibition and immune stimulation of cancer cells, and significantly improved the The potential of tumor treatment.
Patent Information
- Application Number
- CN202311527483.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-15
- Publication Date
- 2024-12-06
AI Technical Summary
It is difficult for the prior art to develop efficient and highly selective PARP7 inhibitors, especially in their highly conserved catalytic domains and NAD+ binding sites, resulting in difficulties in the development of selective inhibitors for PARP7.
Through a series of compound reaction steps, including reaction, addition reaction, deaminophenol and substitution reaction of pyridazinone compounds of different protective groups with (2S)-2-amino-1-propanol, ultimately in basic The target compound Atamparib (RBN-2397) was synthesized under conditions.
The PARP7 inhibitor RBN-2397, with IC50 less than 3nM and a selectivity of more than 50 times was successfully prepared. It can enhance type I interferon signaling, induce autonomy and immune stimulation of cancer cells, effectively inhibit cancer cell growth and restore interferon signaling, and prevent cancer. Cells escape the immune system.
Smart Images

Figure CN119080752A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of chemical drug synthesis and relates to a preparation method of PARP7 inhibitor Atamparib (RBN-2397). Background Art
[0002] Targeting type I IFN response is an emerging strategy for tumor treatment. PARP7 has been shown to be associated with a variety of cancers. When cells are under stress (for example, healthy cells are infected by viruses or cancer cells have genomic instability), PARP7 expression levels rise. Its function is to inhibit the cell's type I interferon stress response. In tumors, the expression of PARP7 allows tumor cells to escape aging and avoid being recognized and eliminated by the immune system. PARP7 expressed in cancer cells can prevent type I IFN expression and anti-tumor immunity. PARP7 is expressed in cancer but not in normal tissues. For example, the frequency of amplification in squamous NSCLC (SCCL) is 15-29%, 6-14% in HNSCC, 4-10% in cervical cancer, and 3-15% in ovarian cancer (all subtypes). It has been shown to be overactive in tumors and play a key role in cancer cell survival. Inhibiting PARP7 can effectively inhibit cancer cell growth, restore interferon signals, and effectively prevent cancer cells from escaping the immune system.
[0003] The main obstacle to developing selective inhibitors of PARP7 or other PARPs is the highly conserved structural domains in the PARP catalytic domain; although the sequence homology is only about 50%, their structures are highly conserved, especially in the NAD + Binding site (the main binding site for most PARP inhibitors). PARP1, PARP7 and PARP14 have been studied more. Currently, only one PARP7 inhibitor has entered clinical research. This field has great research value and space. So far, only one PARP7 selective inhibitor, RBN-2397, has entered clinical phase I research. RBN-2397 is a potent, selective, and highly orally bioavailable PARP7 inhibitor that can induce cancer cell autonomy and immune stimulation by enhancing type I interferon (IFN) signaling. IC of PARP7 50 Less than 3nM, more than 50 times more selective than other family members. RBN-2397 can also induce CD8T cell-dependent tumor-specific adaptive immune memory in immune-competent mouse cancer models. RBN-2397 is currently being studied clinically alone or in combination with the PD-1 inhibitor pembrolizumab. Summary of the invention
[0004] In view of the above situation, the preparation of PARP7 inhibitor Atamparib (RBN-2397) is very important. The inventors solved the technical problem of the compound through experimental research, and the reaction route is as follows:
[0005]
[0006] The present invention comprises the following steps
[0007] (a) The key intermediate (2a-2c) is obtained by reacting the pyridazinone compound raw material (1a-1f) containing different protective groups with (2S)-2-amino-1-propanol (6) in the presence of a base.
[0008]
[0009] (b) Compound (2) undergoes addition reaction with acryloylpiperazine compounds (7a-7c) containing different protecting groups to obtain compounds (3a-3i)
[0010]
[0011]
[0012] (c) Compound (3) is deprotected under acidic conditions to obtain compound (S)-5-((1-(3-oxo-3-(piperazin-1-yl)propoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one (4)
[0013]
[0014] (d) Finally, a substitution reaction with 2-halogenated-5-(trifluoromethyl)pyrimidine (8a-8c) was carried out under alkaline conditions to obtain the target compound Atamparib (RBN-2397) (5)
[0015]
[0016] Specific experimental method
[0017] The present invention is further described below by way of examples, but the contents of the present invention are not limited thereto.
[0018] Example 1
[0019]
[0020] Step A Preparation of (S)-5-((1-hydroxypropan-2-yl)amino)-2-(4-methoxybenzyl)-4-(trifluoromethyl)pyridazin-3(2H)-one (2)
[0021] The compound 5-chloro-2-(4-methoxybenzyl)-4-(trifluoromethyl)pyridazine-3(2H)-one (5.0 g, 15.69 mmol) was weighed into a 100 mL reaction bottle, ethanol (40 mL) was added to dissolve, and then triethylamine (4.4 mL, 31.38 mmol) and (2S)-2-amino-1-propanol (1.19 g, 15.69 mmol) were added in sequence. The mixture was stirred at 60° C. for 4 h, concentrated in vacuo, and the residue was purified by column chromatography to obtain the compound (S)-5-((1-hydroxypropan-2-yl)amino)-2-(4-methoxybenzyl)-4-(trifluoromethyl)pyridazine-3(2H)-one (5.04 g, yield 90%). LC-MS (ESI): m / z=357.3[M+H] + .
[0022] Step B Preparation of (S)-tert-butyl 4-(3-(2-((1-(4-methoxybenzyl)-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propanoyl)piperazine-1-carboxylate (3)
[0023] (S)-5-((1-hydroxypropan-2-yl)amino)-2-(4-methoxybenzyl)-4-(trifluoromethyl)pyridazin-3(2H)-one (250 g, 699 mmol), tert-butyl 4-acryloylpiperazine-1-carboxylate (168 g, 699 mmol), and CS2CO3 (273 g, 838 mmol) were dissolved in CH3CN (1.4 L) and stirred at 25°C for 24 h. The solid was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound (S)-tert-butyl 4-(3-(2-((1-(4-methoxybenzyl)-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propanoyl)piperazine-1-carboxylate (343 g, yield 83%). LC-MS (ESI): m / z = 597.6 [M+H] + .
[0024] Step C Preparation of (S)-5-((1-(3-oxo-3-(piperazin-1-yl)propoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one (4)
[0025] A solution of (S)-tert-butyl 4-(3-(2-((1-(4-methoxybenzyl)-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propanoyl)piperazine-1-carboxylate (214 g, 358 mmol) and TfOH (115 mL) in TFA (1 L) was stirred at 25 °C for 2 h. Then 4 L of water was added to quench the reaction, and the resulting solution was extracted with 2×1 L of EtOAc. The pH value of the organic layer was adjusted to 8 with aqueous K2CO3 solution, the organic layers were combined and concentrated, and the residue was transferred to a silica gel column and separated with ethyl acetate / petroleum ether. The fractions were combined and concentrated, and then further washed with EtOAc to give (S)-5-((1-(3-oxo-3-(piperazin-1-yl)propoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one (89 g, yield 66%). LC-MS (ESI): m / z=377.4 [M+H] + .
[0026] Step D Preparation of Atamparib (RBN-2397) (5)
[0027] A solution of 2-chloro-5-(trifluoromethyl)pyrimidine (100 g, 550 mmol), (S)-5-((1-(3-oxo-3-(piperazin-1-yl)propoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one (196 g, 520 mmol) and K2CO3 (151.8 g, 1100 mmol) in NMP (800 mL) was stirred at 80°C for 1 hour, and then 2.5 L H2O was added. The solid was collected by filtration to obtain the target compound Atamparib (RBN-2397) (248 g, yield 91%), LC-MS (ESI): m / z=523.4 [M+H] + . 1 HNMR(400MHz,DMSO)δppm 1.15(d,3H)2.60(t,2H)3.49(d,2H)3.55(dd,4H)3.63-3.74(m,2H)3.74-3.82(m,2H)3 .82-3.91(m,2H)4.15(dt,1H)6.29(dd,1H)7.92(s,1H)8.38-9.18(m,2H)12.46(s,1H).
[0028] Example 2
[0029]
[0030] The same method as step A and step B in Example 1 was used to prepare compound (S)-4-(3-(2-((1-(4-methoxybenzyl)-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propanoyl)piperazine-1-carboxylic acid tert-butyl ester (3):
[0031] Step C Preparation of (S)-2-(4-methoxybenzyl)-5-((1-(3-oxo-3-(4-piperazin-1-yl)propoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one (4)
[0032] A solution of (S)-tert-butyl 4-(3-(2-((1-(4-methoxybenzyl)-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propanoyl)piperazine-1-carboxylate (59 g, 0.1 mol) in dichloromethane (150 ml) was added to a three-necked flask, followed by the addition of trifluoroacetic acid (12.54 g, 0.11 mol). The resulting mixture was stirred at room temperature for 10 hours. After the reaction was completed, the mixture was heated to 40°C with hydrogen carbonate. The mixture was quenched with sodium solution (100 ml), then extracted with dichloromethane (150 ml×2), and the obtained organic phase was washed with sodium bicarbonate, dried over anhydrous magnesium sulfate, and concentrated to give (S)-2-(4-methoxybenzyl)-5-((1-(3-oxo-3-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)propoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one (47 g, yield 94%). LC-MS (ESI): m / z=496.5[M+H] +
[0033] Step D Preparation of (S)-2-(4-methoxybenzyl)-5-((1-(3-oxo-3-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)propoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one (5)
[0034] A solution of 2-chloro-5-(trifluoromethyl)pyrimidine (100 g, 550 mmol), (S)-2-(4-methoxybenzyl)-5-((1-(3-oxo-3-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)propoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one (258 g, 520 mmol) and K2CO3 (151.8 g, 1100 mmol) in NMP (800 mL) was stirred at 80°C for 1 hour, and then 2.5 L of H2O was added. The solid was collected by filtration to give (S)-2-(4-methoxybenzyl)-5-((1-(3-oxo-3-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)propoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one (301.5 g, yield 90%), LC-MS (ESI): m / z=643.6 [M+H] + .
[0035] Step E Preparation of Atamparib (RBN-2397) (6)
[0036] A solution of (S)-2-(4-methoxybenzyl)-5-((1-(3-oxo-3-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)propoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one (230 g, 358 mmol) and TfOH (115 mL) in TFA (1 L) was stirred at 25°C for 2 h. Then 4 liters of water were added to quench the reaction, and the resulting solution was extracted with 2×1 L of EtOAc. The pH value of the organic layer was adjusted to 8 with aqueous K2CO3 solution, the organic layers were combined and concentrated, and the residue was transferred to a silica gel column and separated with ethyl acetate / petroleum ether. The fractions were combined and concentrated, and then further washed with EtOAc to obtain the target compound Atamparib (RBN-2397) (112 g, yield 60%). LC-MS (ESI): m / z = 523.4 [M+H] + .
[0037] The above examples are only used to illustrate the embodiments of the present invention, but the present invention is not limited to the above examples. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected, and the scope of the present invention to be protected is defined by the claims and their equivalents.
Claims
1. A method for preparing a PARP7 inhibitor Atamparib (RBN-2397), characterized in that: The specific steps are: 1) The key intermediate compound (2) is obtained by reacting pyridazinone compounds containing different protective groups with (2S)-2-amino-1-propanol in the presence of a base. 2) Compound (2) undergoes addition reaction with acryloylpiperazine compounds (7) containing different protecting groups to obtain compound (3) 3) Compound (3) is deprotected under acidic conditions to obtain compound (S)-5-((1-(3-oxo-3-(piperazin-1-yl)propoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one (4) 4) Finally, a substitution reaction with 2-halogenated-5-(trifluoromethyl)pyrimidine (8) was carried out under alkaline conditions to obtain the target compound Atamparib (RBN-2397) (5) 2. The method for preparing the PARP7 inhibitor Atamparib (RBN-2397) according to claim 1, characterized in that: In step (1), the reaction temperature is selected from 10-200°C, the reaction time is selected from 0-72h, and the solvent is selected from one or more of N,N-dimethylformamide (DMF), dichloromethane, ethanol, etc. The alkali agent is selected from one or more of sodium carbonate, potassium carbonate, triethylamine, sodium hydroxide, potassium hydroxide, sodium bicarbonate, sodium hydride, etc. Purification can be selected from washing the filter cake during filtration, column, pulping or recrystallization.
3. The method for preparing the PARP7 inhibitor Atamparib (RBN-2397) according to claim 1, characterized in that: In step (2), the reaction temperature needs to be controlled within an appropriate range, usually room temperature or heated until the reactants boil. The solvent is selected from one or more of water, alcohols, ethers, etc. The catalyst is selected from an acidic catalyst and a basic catalyst, specifically one of concentrated sulfuric acid, phosphoric acid, sodium hydroxide, potassium hydroxide, etc., and a metal salt catalyst can also be selected. Purification can be selected from column, pulping, Prep-TLC, Prep-HPLC or recrystallization.
4. The method for preparing the PARP7 inhibitor Atamparib (RBN-2397) according to claim 1, characterized in that: In step (3), the reagent is trifluoroacetic acid (TFA) or hydrogen chloride gas, the reaction solvent is selected from one or more of DCM, 1,2-dichloroethane, chlorobenzene, acetonitrile, THF, 2-MeTHF, DMF, DME, 1,4-dioxane, H2O, NMP, DMAC, and DMSO, and the molar ratio of the compound to the deamino protecting group reagent is 1:1-1:3; the reaction temperature is room temperature, and the purification can be selected from column, slurrying, Prep-TLC, Prep-HPLC, or recrystallization.
5. A method for preparing a CETP inhibitor Obicetrapib (AMG-899) according to claim 1, characterized in that: In step (4), the base is selected from one or more of potassium tert-butoxide, sodium tert-butoxide, potassium tert-amyl alcohol, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, cesium carbonate, cesium bicarbonate, potassium phosphate and dipotassium hydrogen phosphate. In some preferred embodiments, the base is selected from potassium bicarbonate and potassium carbonate. The solvent is selected from one or more of 1-methyl-2-pyrrolidone (NMP), N,N-dimethylformamide (DMF) and N,N-dimethylaniline (DMA), the reaction temperature is selected from 60-130°C, and the purification can be selected from column, pulping, Prep-TLC, Prep-HPLC or recrystallization.
